MA与DA方案诱导缓解急性非淋巴细胞白血病的临床观察  

Clinical observation about MA and DA therapies for acute nonlymphocytic leukemia

作　　者：王璇[1] 张慧莹[1] 崔海鹏[1] 

机构地区：[1]北华大学附属医院血液科,吉林吉林132011

出　　处：《中国现代医学杂志》2008年第14期2072-2073,2077,共3页China Journal of Modern Medicine

摘　　要：目的比较柔红霉素联合阿糖胞苷(DA)、米托蒽醌联合阿糖胞苷(MA)治疗急性非淋巴细胞白血病的疗效和不良反应。方法采用随机配对研究方法观察60例急性非淋巴细胞白血病的治疗效果和不良反应,一组29例采用MA方案,另一组31例对照组采用DA方案。结果二者缓解率上差异无显著性(P>0.05)。两组不良反应在发热,出血,恶心、呕吐,上呼吸道感染上差异无显著性(P>0.05),但DA较MA易出现心脏毒性,差异有显著性(P<0.05)。结论MA可作为急非淋的一线化疗方案。[Objective] To compare the efficacy and adverse effects of DA with MA in the treatment of acute nonlymphocytic leukemia（ANLL）. [Methods] Case-control study was used. 60 cases of previously untreated ANLL patients were randomly divided into two groups,i.e., DA and MA treated group. 29 cases in the treatment group took MA therapy while 31 cases in the control group received DA therapy. [Result] In both groups there was no significant difference in the complete remission （CR） rate and the total response rate（P 〉0.05）. As to the adverse effects of both groups, there was no significant difference in fever, bleeding, nausea and emesis, upper respiratory infection etc （P〉0.05）. But DA presented heart toxicity more easily than MA（P 〈0.05）. [Conclusion] It is suggested that MA regimen should be the first regimen of choice for acute nonlymphocytic leukemia.

关 键 词：白血病 急性 非淋巴 米托蒽醌 柔红霉素 

分 类 号：R552[医药卫生—血液循环系统疾病]